Bayer Pharma Aktiengesellschaft

Institut Fur Diagnostikforschung Gmbh an Der Freien Universitat Berlin

Schering Aktiengesellschaft

Bayer Intellectual Property Gmbh

Institut Fur Diagnostikforschung Gmbh

Other

Bayer Schering Pharma Ag

Philogen S.p.a.

Institut Fur Diagnosikforschung Gmbh

Freien Universitat Berlin

Der Freien Universitat Berlin

Christoph-Stephan Hilger

Ulrich Speck

Kai Licha

Wolfhard Semmler

Thomas Frenzel

Markus Berger

Olaf Panknin

Gregor Jost

Hubertus Pietsch

Jessica Lohrke

Johannes Platzek

Reiner Fischer

Ulf Bömer

Kai Thede

Ningshu Liu

Ludger Dinkelborg

Raju Mohan

Ursula Mönning

Philip Lienau

Gerhard Siemeister

Hans Briem

Arne Scholz

Richard Horuk

Joseph E Hesselgesser

Ulrich Niedballa

Wahed Ahmed Moradi

Knut Eis

Anne Mengel

Mark Jean Gnoth

Detlev Sülzle

Simon Holton

Marion Hitchcock

Christian Stegmann

Dieter Heldmann

Matthias Friebe

Stefan Prechtl

Björn Riefke

Detlev Suelzle

Harald Dinter

Wolfgang Kramp

Bernd Johannsen

Peter Maeding

Joerg Steinbach

Meredith Halks-Miller

Hans-Martin Schier

Luciano Zardi

Barbara Carnemolla

Friedhelm Blume

Laura Borsi

Vera Pütter

Patrizia Castellani

Enrica Balza

Cornelia Preusse

Bj&ouml;rn Riefke

Amaury Ernesto Fernández-Montalván

Maher Najjar

Heribert Miklautz

Gunnar Tepe

Bernhard Noll

Stephan Duda

Heidemarie Goerner

Dietmar Berndorff

Thomas Fenzel

L Ist Naz Per La Ricerca Sul Cancro Zardi

Laura Ist Naz Per La Ricerca Sul Cancro Borsi

B Inst Naz Per Ricerca Sul Cancro Carnemolla

P Ist Naz Per La Ricerca Sul Cancro Castellani

Enrica Ist Naz Per La Ricerca Sul Cancro Balza

Dieter Schering Aktiengesellschaft Moosmayer

Giovanni Philogen Srl Neri

Detlev Sulzle

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Gadolinium chelate compounds for use in magnetic resonance imaging

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents. 

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The invention relates to substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-ones, in particular for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of neoplastic disorders.

Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one

The invention relates to (5s,8s)-3-(4'-chloro-3&#x2032;-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders.

(5s,8s)-3-(4'-chlor-3&#x2032;-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one (compound A) for treatment

The invention relates to substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones of the formula (Ia) for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumor disorders. The invention also relates to novel compounds of the formula (I) in which W, X, Y, Z, A, B, D and G have the meanings given above,to a plurality of processes and intermediates for their preparation, and to their use as pesticides and/or herbicides and/or fungicides. The invention also relates to selectively herbicidal compositions comprising, firstly, the halogen-substituted spirocyclic ketoenols and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to the boosting of the action of crop protection compositions comprising, in particular, halogen-substituted spirocyclic ketoenols, through the addition of ammonium salts or phosphonium salts and optionally penetrants, to the corresponding compositions, to processes for producing them and to their application in crop protection as pesticides and/or fungicides and/or for preventing unwanted plant growth.

Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy

The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.

Selective targeting of tumor vasculature using antibody molecules

This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.

Near infrared imaging agent

In-vivo diagnostic method by near infrared radiation

In-vivo diagnostic method by means of near infrared radiation

Growing community of inventors

Berlin, Germany

Christoph-Stephan Hilger